QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Nu.Q NETs Assay Selected for France’s National Sepsis Detection Initiative
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that its Nu.Q® NETs H3.1 assay has been chosen as the sole biomarker for “DETECSEPS,” a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million (~$7.3 million) grant, aims to transform emergency care for patients with infection and risk of sepsis progression. Professor Djillali Annane, Intensive Care Department, IHU SEPSIS, Raymond Poincaré Hospital (AP-HP) and Scientific Director of DETECSEPS, noted that combining Volition’s Nu.Q® H3.1 biomarker with a clinical score (NEWS2) could improve…